Focus on Your Breakthrough - We Ensure Reliable Drug Delivery

Digital illustration of lungs with connected data structures and technical graphics, featuring the eFlow® Technology logo.

Bringing new innovative inhalation therapies to market is a long and risky process. The interaction of drug and device involves a high degree of complexity where both technical and regulatory requirements must be met. Having this in mind, choosing the ideal nebulizer and device partner can make all the difference and reduce overall development risks.

Focus on your formulation, knowing a reliable partner takes care of the device and supports you through the development.


Rely on PARI as a trusted partner for the most suitable nebulizer - ensuring the best fit to your drug.

Schematic illustration showing the combination of a drug formulation with an eFlow Technology mesh nebulizer for targeted aerosol delivery to the lungs.

 

 

  1. March, 2010

    Altera® for Cayson®

    Approved in US, EU, CAN

  2. July, 2010

    eFlow®rapid for ColiFin®

    Approved in EU

  3. March, 2015

    Tolero® for Vantobra®

    Approved in EU

  4. March, 2015

    Zirela® for Quinsair™

    Approved in CAN, EU

  5. September, 2018

    Lamira® for ARIKAYCE®

    Approved in US

  6. October, 2020

    Lamira® for ARIKAYCE®

    Approved in EU

  7. March, 2021

    Lamira® for ARIKAYCE®

    Approved in JPN

  8. October, 2022

    Tolero® for Vantobra®

    Approved in CH

Why PARI is Your Trusted Partner

  • Proven Expertise: 25+ years of experience and a strong track record in mesh nebulizer technology
  • High-End Mesh Technology: eFlow Technology defines the state-of-the-art in performance
  • Highest Flexibility: A broad platform concept for the most efficient and adaptable nebulizers
  • End-to-End Support: In-house aerosol services, regulatory and usability expertise for rapid customization
  • Reliable Supply: High-quality manufacturing at two PARI sites for clinical and commercial success

“We take clinical risk but don’t want to add device risks. That’s why we like it when our portfolio-companies use eFlow.”

Investor (during ATS 2024 podium discussion)

 

 

"When I mention that we work with PARI all discussions on device risk at Wallstreet are over."

CEO (during ERS 2024)

 

Customization is Key

Learn what made Avalyn Pharma decide to go with a customized eFlow Technology nebulizer. Spoiler: ~8.5 min per dose with an eFlow Open System nebulizer vs ~27 DPI inhalations or 45–60 min on general-purpose nebulizers.

Read more

white Pixel

Ongoing Disclosed Projects –
Your Success Could Be Next

  • ARIKAYCE® (Phase III label extension)

    Mycobacterium avium complex (MAC) Lung disease

    PrePh IPh IIPh IIINDA/BLA
  • Zambon Logo

    L-CsA-I

    Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation

    PrePh IPh IIPh IIINDA/BLA
  • Zambon Logo

    Inhaled CMS

    Non-CF Bronchiectasis

    PrePh IPh IIPh IIINDA/BLA
  • SAVARA Logo

    Molgramostim

    Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

    PrePh IPh IIPh IIINDA/BLA
  • Renovion Logo

    ARINA-1

    Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation

    PrePh IPh IIPh IIINDA/BLA
  • Renovion Logo

    ARINA-1

    Non-CF Bronchiectasis

    PrePh IPh IIPh IIINDA/BLA
  • avalyn Logo

    AP01

    Progressive Pulmonary Fibrosis (PPF)

    PrePh IPh IIPh IIINDA/BLA
  • avalyn Logo

    AP02

    Idiopathic Pulmonary Fibrosis (IPF)

    PrePh IPh IIPh IIINDA/BLA
  • ReCode Logo

    RCT1100

    Primary Ciliary Dyskinesia (PCD)

    PrePh IPh IIPh IIINDA/BLA

More than 20 undisclosed projects in pre-clinical and 
clinical development with various drug classes

40% Biologics
20% Nucleotides
40% Small molecules


Need More Details Before Reaching Out?

Discover how PARI supports you in achieving impactful clinical results and commercial success

  • A blue microfluidic device with glowing green light interacts with digital data and molecular structures.

    Customization

    How our platform supports your drug development process

  • A PARI inhaler and a smartphone displaying breathing instructions are overlaid with digital data, molecular structures, and abstract blue patterns.

    Usability

    To improve patient adherence and clinical outcomes

  • PARI provides comprehensive analytical services for product development in combination with nebuliser customisation from early phase to submission and commercialisation.

    Lasting Reliability

    By long-term supply & consistent quality for commercial success

  • Mobile phone and laptop displaying data analytics dashboards over a digital background with hexagonal molecular structures and binary code, symbolizing healthcare technology and data analysis.

    Digital Technologies

    To understand how patients take their drug and boost therapy effectiveness


Let`s partner for success!

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.

PARI Business Development Team